NCT04142892View on ClinicalTrials.gov

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Breast Cancer
Interventions
DRUG

Onapristone

50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)

Trial Locations (4)

25198

Hospital Universitari Arnau de Vilanova de Lleida, Lleida

08035

Hospital Universitari Vall d'Hebron, Barcelona

Unknown

Hospital Clínic de Barcelona, Barcelona

Hospital Universitario Sant Joan de Reus, Tarragona

All Listed Sponsors
lead

SOLTI Breast Cancer Research Group

OTHER

NCT04142892 - Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer | Biotech Hunter | Biotech Hunter